CagriSema and NAD for menopause weight loss: what the data says

What's this video probably claiming?

Based on the hashtags and caption pattern, @thechristinablog is likely pitching cagrilintide (a long-acting amylin analogue) combined with semaglutide, the combination known as CagriSema, as a weight loss solution specifically suited to perimenopausal and postmenopausal women. The "DM me for more info" call-to-action is a red flag. That phrasing is the standard playbook for unlicensed peptide brokers operating in the grey market. The NAD hashtag suggests she may also be bundling NAD+ or NMN as a complementary anti-aging or metabolic add-on. The framing around midlife women is smart marketing: this demographic is underserved by conventional medicine and actively searching for answers on metabolic changes tied to estrogen decline. But smart marketing and clinical evidence are two different things.

What does the science actually show?

CagriSema does have real trial data behind it. The SCALE CAGRISEMA phase 3 trial, published in The Lancet in 2024 (Lau et al.), showed that weekly subcutaneous cagrilintide 2.4 mg combined with semaglutide 2.4 mg produced approximately 22.7% body weight reduction over 68 weeks in adults with obesity, outperforming semaglutide alone (15.7% in STEP 1). That is a genuinely impressive number. However, this trial population was not limited to menopausal women, and the drug is not FDA-approved. It is still in phase 3 development. The combination is not legally available as a compounded product in the U.S. under current FDA guidance. NAD+ supplementation research is far thinner. A 2022 randomized trial by Dollerup et al. in Cell Reports Medicine found no significant metabolic benefit in metabolically healthy overweight adults taking oral NMN at 1,000 mg per day for 10 weeks. The menopause-specific NAD data is essentially nonexistent at clinical scale.

Where does the social media noise diverge from clinical reality?

Several divergences stand out here. First, CagriSema is not the same as semaglutide alone, and it is not a compounded product you can simply "get" through a DM. Implying easy access is at best premature and at worst directing people toward unregulated sources. Second, the menopause framing conflates two separate biological problems: estrogen-related metabolic changes and GLP-1 receptor agonist pharmacology. There is no published RCT data showing CagriSema was specifically tested in perimenopausal women as a primary population. Third, stacking CagriSema with NAD+ is not clinically validated anywhere in the published literature. The combination carries unknown interaction risks, and promoting it as a menopause protocol is speculation dressed as health optimization. Fourth, the "for research purposes" hashtag does not create a legal or ethical shield. Regulators including the FDA and FTC have explicitly noted that disclaimers do not neutralize actionable health claims.

What should you actually know?

If you are a perimenopausal or postmenopausal woman struggling with weight gain and metabolic changes, your frustration is real and legitimate. Estrogen decline does alter fat distribution, insulin sensitivity, and appetite signaling. GLP-1 receptor agonists like semaglutide (FDA-approved as Wegovy at 2.4 mg weekly) are clinically validated tools for this population, and a 2023 analysis in Menopause journal (Rupa et al.) noted meaningful weight reduction in midlife women on semaglutide in real-world cohorts. CagriSema may eventually be a meaningful advancement, but it is not available legally and safely through social media DMs right now. NAD supplementation has a plausible mechanism but weak clinical evidence at the doses and contexts being promoted online. Work with a licensed clinician who can access approved therapies, monitor labs, and adjust based on your individual hormonal picture.